2011 News | Events | Industry Updates
Labelling molecules with carbon-14 allows them to be detected in situ, providing an essential tool for determining the behaviour and fate of chemical compounds in organisms and in the environment.
Simon has over 30 years of commercial experience within the life sciences industry, and brings with him a strong mix of technical, strategic and business development expertise.
Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA (Paris, France), using Selcia’s fragment screening technology.
Selcia appoints Simon Saxby as its Chief Executive Officer (CEO). He will assume his position in April and takes over from Dr Hans Fliri who retains his role as Chairman of the Board.